It is not investors but close collaborations with the established pharmaceutical industry that are going to ensure the continued operation of the Danish biotech company Ascendis Pharma, the company chairman tells Danish business daily Børsen, after Ascendis emerged from 2011 with a DKK 90.1 million deficit. The shareholders equity was DKK 125.7 million at the end of 2011 against 174.3 million at the end of 2010.
“We are backed by great investors, but we also know that we have to face facts. So our business strategy is meant to secure a balance between income and expenditure, so expenses aren’t financed by our shareholders but through collaborations,” chairman of the board Michael Wolff Jensen tells Børsen.
Mere fra MedWatch
Med en lav værdiansættelse, en høj strukturel værdi og ingen dominerende aktionærer giver det god mening, hvis internationale kapitalfonde og industrielle spillere lige nu lurer på at købe høre- og lydkoncernen GN Store Nord, mener to analytikere, men om det reelt kommer til at ske, tvivler de dog på.